Home

Crossing the Blood-Brain Barrier with Breakthrough Therapeutics

AngioChem is a clinical-stage biotechnology company discovering and developing breakthrough drugs that are uniquely capable of crossing the blood-brain barrier to treat brain diseases. The company’s proprietary platform for Engineered Peptide Compounds (EPiC) offers a completely new, innovative way to develop drugs to cross the blood-brain barrier and positions AngioChem as a leader in this field. Based on the EPiC platform, AngioChem has created a deep and broad product pipeline, including small and large molecules, for the treatment of a wide range of brain diseases and related disorders, including brain cancer, cancer metastases, neurodegenerative and metabolic diseases.